• Progression-free survival [ Designated as safety issue: No ]
  

• Toxicities [ Designated as safety issue: Yes ]
  
• Response rate [ Designated as safety issue: No ]
  
• Overall survival [ Designated as safety issue: No ]
  
• Clinical benefits [ Designated as safety issue: No ]
  
• Quality of life by QLQ-C30 [ Designated as safety issue: No ]
  
• Biomarkers of response [ Designated as safety issue: No ]
  

OBJECTIVES:

Primary

• Compare progression-free survival.

Secondary

• Compare toxicities.
• Compare response rate.
• Compare overall survival.
• Evaluate clinical benefits.
• Compare quality of life.
• Identify biomarkers that predict therapeutic response.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral sorafenib tosylate twice daily and gemcitabine hydrochloride IV once weekly for 7 weeks followed by 1 week of rest (course1). For the next 2 courses, patients receive gemcitabine hydrochloride weekly for 3 weeks followed by 1 week of rest and sorafenib tosylate twice daily.
• Arm II: Patients receive oral placebo twice daily and gemcitabine hydrochloride as in arm I.

After completing 3 courses of therapy, patients in both arms who have stable or responding disease may continue to receive sorafenib tosylate or placebo in the absence of disease progression or unacceptable toxicity.

DISEASE CHARACTERISTICS:

Inclusion criteria:

• Diagnosis of adenocarcinoma of the pancreas

  • Locally advanced or metastatic disease
• Measurable disease, defined as at least 1 lesion measurable by RECIST criteria

Exclusion criteria:

• Brain metastases

PATIENT CHARACTERISTICS:

Inclusion criteria:

• WHO performance status 0-2
• Absolute neutrophil count > 1,500/mm^3
• Platelet count > 100,000/mm^3
• Creatinine < 1.5 times normal
• Transaminases < 2 times normal (5 times normal if liver metastases)
• Total bilirubin < 1.5 times normal
• Fertile patients must use effective contraception

Exclusion criteria:

• Pregnant or nursing
• Intestinal occlusion
• Prior inflammatory intestinal disease
• Crohn's disease
• Hemorrhagic rectal colitis
• Peripheral neuropathy > grade 2

• Other severe illness, including any of the following:

  • Unstable cardiac disease, even if treated
  • Psychological or neurological disease including dementia
  • Uncontrolled active infection
  • Other severe illness that would compromise study participation
• Impossible to receive study therapy due to geographical, social, or psychological reasons
• Other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

• See Disease Characteristics
• At least 6 months since prior chemotherapy or radiochemotherapy
• At least 4 weeks since prior radiotherapy and/or surgery

Exclusion criteria:

• Prior therapy for advanced disease
• Prior inhibitors of kinase signaling (e.g., ras/raf, MEK, AKT, mTOR, or farnesyl transferase)
• Prior inhibitors of angiogenesis (e.g., bevacizumab)
• Prior organ graft or allogeneic transplantation
• Prior extensive intestinal resection
• Concurrent participation in another therapeutic study
• Concurrent inductors of CYP3A4 (e.g., barbiturates, anti-epileptics, or rifampicin)